Masimo Q3 healthcare revenue up 11.7% CC; raises FY non-GAAP EPS guidance to $3.95-$4.10

MASIMO CORP

2024-Q3 EPS reported $0.82 revenue$1,493,700,000

Healthcare revenue $343.3M (+11.7% CC); total revenue $504.6M; 60,500 board/instrument shipments.
GAAP EPS $0.18; Non-GAAP EPS $0.98; GAAP operating income $30.1M, non-GAAP $80.8M.
Raised FY2024 non-GAAP EPS guidance to $3.95-$4.10 from prior $3.80-$4.00; operating income $325-$336M.
Narrowed FY total revenue guidance to $2.075-$2.105B from $2.085-$2.135B; healthcare $1.390-$1.400B.
Interim CEO cites ongoing portfolio review, R&D focus on sizable markets, and strategic review of consumer business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.